Infinium Pharmachem IPO: GMP, Price, Dates & size

0
611
Rate this post

Infinium Pharmachem Limited, established in 2003, is a manufacturer and supplier of iodine derivatives, APIs, and iodination reaction-based bulk drugs. The company provides R&D services as well as commercial-scale manufacturing and packaging for various industries, including pharmaceuticals, agrochemicals, nutraceuticals, specialty chemicals, and others. Its manufacturing plant is located in Gujarat, India, spanning over 4100 square meters of plot area. The facility is FDA certified and GMP compliant, with the ability to produce complex iodine derivatives. 

Infinium Pharmachem Limited has a wide range of products, including over 200 iodine derivatives and 7 APIs, which it supplies to more than 15 countries worldwide. With a commitment to quality and compliance, the company has established itself as a reliable and trusted supplier of iodine derivatives and other chemical products. Its focus on R&D and manufacturing capabilities has enabled it to cater to the diverse needs of various industries, making it a preferred partner for many customers. 

Infinium Pharmachem IPO Details 

IPO Date Mar 31, 2023 to Apr 5, 2023 
Listing Date Apr 17 2023
Face Value ₹10 per share 
Price ₹135 per share 
Lot Size 1000 Shares 
Total Issue Size 1,875,000 shares 
(aggregating up to ₹25.26 Cr) 
Fresh Issue 1,875,000 shares 
(aggregating up to ₹25.26 Cr) 
Employee Discount Rs 13.5 per share 
Issue Type Fixed Price Issue IPO 
Listing At NSE SME 
ITCONS E-Solutions IPO: GMP, Price, Dates and size
Infinium Pharmachem

Infinium Pharmachem IPO Tentative Dates 

IPO opens on Mar 31, 2023, and closes on Apr 5, 2023

Event Tentative Date 
Opening Date Mar 31, 2023 
Closing Date Apr 5, 2023 
Basis of Allotment Apr 11, 2023 
Initiation of Refunds Apr 12, 2023 
Credit of Shares to Demat Apr 13, 2023 
Listing Date Apr 17, 2023 
UPI Mandate Confirmation Cut-Off Time 5.00 PM on the issue closing day 

Industry Overview 

The pharmaceutical industry in India has been growing at a compound annual growth rate (CAGR) of around 10% over the past few years. This growth is attributed to factors such as a large patient population, increasing healthcare awareness, and the rising prevalence of chronic diseases. In addition, the government’s initiatives to promote affordable healthcare and the increasing focus on research and development activities are driving the growth of the industry. 

As a manufacturer and supplier of iodine derivatives, APIs, and iodination reaction-based bulk drugs, Infinium Pharmachem Limited operates in the pharmaceutical and chemical industries. The company’s focus on R&D and manufacturing capabilities has enabled it to cater to the diverse needs of various industries, making it a preferred partner for many customers. With its wide range of products and services, the company is well-positioned to benefit from the growth opportunities in the pharmaceutical and chemical industries. 

Company Financials  

Period Ended Total Assets Total Revenue Profit After Tax Net Worth Total Borrowing 
31-Mar-20 2,244.60 3,941.64 93.40 424.74 566.17 
31-Mar-21 3,418.27 7,115.37 272.48 702.32 579.47 
31-Mar-22 5,899.95 10,005.25 610.64 1,310.22 1,385.01 
30-Sep-22 7,075.71 7,985.39 551.01 1,855.77 1,614.71 
Amount in ₹ Lakhs 

Objects of the Issue 

The proceeds from the fresh issue will be utilized for the following objects: 

1. Marketing and branding expenses (including registration in reach – Europe, and other marketing expenses). 

2. Repayment of some of the existing loans and expansion of units. 

3. To meet incremental working capital requirements. 

4. To meet public issue expenses. 

Infinium Pharmachem IPO Prospectus

Company Contact Information

Infinium Pharmachem Limited
38 G.I.D.C Sojitra,
Taluka – Sojitra,
Dist. – Anand – 387240
Phone: +91-2692-238849
Email: info@infiniumpharmachem.com
Websitehttps://infiniumpharmachem.com/

Infinium Pharmachem IPO Registrar

Bigshare Services Pvt Ltd

Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Websitehttps://www.bigshareonline.com/

Infinium Pharmachem IPO Lead Manager(s)

  1. Swastika Investmart Ltd (Past IPO Performance)

LEAVE A REPLY

Please enter your comment!
Please enter your name here